Investor Presentation Q1 2022

16 Investor presentation First three months of 2022 R&D milestones for 2022 Diabetes care Project OzempicⓇ 2.0 mg FDC Sema - OW GIP CagriSema T2DM RybelsusⓇ Icodec Novo NordiskⓇ Clinical milestones1 Q1 2022 US decision Q2 2022 Q3 2022 Regulatory milestones¹ Q4 2022 Phase 1 results Phase 2 results Ideal Pump insulin Phase 1 results Oral GLP-1/GIP agonist Phase 1 initiation < Obesity care SELECT CVOT Rare disease CagriSema LA-GDF15 Sogroya® (somapacitan) Mim8 Concizumab Eclipse/Ndec Other serious chronic diseases PRX004 (ATTR-CM) CN submission Phase 3a results Phase 1 results Potential interim analysis Phase 3 initiation Phase 1 results US/EU/JP submission (GHD) Phase 1/2 results Phase 3 treatment² Phase 3a results (HWI) ✓ US submission (HwI) Phase 2 initiation Phase 2 initiation Phase 3a results (HA/HB) 1 Expected to be published in the given quarter or in the subsequent quarterly company announcement. 2 First patient first visit in Q4 2021, which is solely for baselining purposes Note: Trial initiations could be impacted by COVID-19; GHD: Growth Hormone Deficiency; sema: semaglutide; HwI: Haemophilia with inhibitors; ATTR-CM: Transthyretin Amyloid Cardiomyopathy; CVOT: Cardiovascular Outcomes Trial

View entire presentation